Clinical Trials Logo

Patent Ductus Arteriosus clinical trials

View clinical trials related to Patent Ductus Arteriosus.

Filter by:

NCT ID: NCT06298344 Recruiting - Clinical trials for Congenital Heart Disease

The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease

Start date: May 1, 2024
Phase: Early Phase 1
Study type: Interventional

Currently, research on the effect of thiamine administration during transcatheter closure on the structure and function of the left ventricle by examining levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in children with left to right shunt congenital heart disease has never been carried out in Indonesia, so it is necessary carried out this research. This research was carried out by administering 100 mg of thiamine once per day to patients post transcatheter closure for 28 days. The parameters assessed were MMP-9, TIMP-1, and echocardiography to assess the structure and function of the left ventricle in CHD patients with left to right shunt lesions.

NCT ID: NCT06256211 Not yet recruiting - Clinical trials for Patent Ductus Arteriosus

Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates

Start date: March 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To compare the effectiveness of rectal vs. intravenous paracetamol in the medical treatment of significant PDA in neonates.

NCT ID: NCT06152796 Not yet recruiting - Clinical trials for Patent Ductus Arteriosus

Comparision Between Paracetamol and Ibuprofen in Closure of Patent Ductus Arteriosus

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

To compare efficacy and safety of paracetamol and ibuprofen for the pharmacological closure of patent ductus arteriosus (PDA) in preterm infants.

NCT ID: NCT06045130 Not yet recruiting - Sepsis Clinical Trials

PUFAs in Preterm Infants

PIPI
Start date: September 21, 2023
Phase:
Study type: Observational

The research endeavors to examine the critical composition of Polyunsaturated Fatty Acids (PUFAs) in premature infants across different gestational stages and under varying disease conditions, and delineate the metabolic attributes of PUFAs in premature infants and their interplay with the onset of diseases. This study anticipates furnishing a theoretical foundation for the rationalization of PUFAs supplementation in premature infants and for informing strategies related to disease prevention and management.

NCT ID: NCT05639309 Recruiting - Premature Birth Clinical Trials

Liver Regional Oxygen Saturation in Preterm Patent Ductus Arteriosus

Start date: January 13, 2023
Phase:
Study type: Observational

This study evaluates the usefulness of liver perfusion and oxygenation status using regional oxygen saturation (RSO2) values obtained via near-infrared spectroscopy in assessing the hemodynamical significance of patent ductus arteriosus in preterm infants.

NCT ID: NCT05264753 Recruiting - Clinical trials for Patent Ductus Arteriosus

PMCF Study to Evaluate Efficacy, Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects

Start date: December 20, 2021
Phase:
Study type: Observational [Patient Registry]

This is a retrospective and prospective, multi-center, international, post marketing follow-up study to evaluate the safety and efficacy of the Occlutech PDA by using Occlutech Occlusions-Pusher (OOP) in patients with patent ductus arteriosus defects. Efficacy and safety of implanted device(s) will be evaluated by vital signs, ECGs, and echocardiography data on baseline/implantation visit (include assessments within 36 hrs. post-procedure), Day 30 to Day 90, 6 months to 1 year, 2 years to 3 years after implantation.

NCT ID: NCT04986839 Recruiting - Clinical trials for Patent Ductus Arteriosus

PAIR (Paracetamol and Ibuprofen Research) Pilot Trial

PAIR
Start date: September 3, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Presence of Patent Ductus Arteriosus is detrimental to an infant born prematurely. The primary objective is to study the efficacy of Paracetamol (proposed new treatment) in treating haemodynamic significant Patent Ductus Arteriosus (hsPDA) in comparison to Ibuprofen (current standard treatment) in preterm infants. Outcome of such treatment will check on the conversion of hsPDA to non-hsPDA. All preterm infants (born at <32 weeks gestational age or birth weight < 1500 grams) with haemodynamically significant patent ductus arteriosus (hsPDA) who are ≤ 28 days old will be included over 2 years. Sample size 32. Secondary outcomes of this study will compare 1) BPD (broncho-pulmonary dysplasia) free survival at 36 weeks post menstrual age (PMA), 2) incidence of complications of prematurity in each group and 3) to record any evidence of adverse effects with Paracetamol or Ibuprofen.

NCT ID: NCT04984057 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

Optimal Dose of Surfactant for Preterm Infants With Respiratory Distress Syndrome

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

In preterm infants with neonatal respiratory distress syndrome (RDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal incidences of bronchopulmonary dysplasia(BPD) and/or death. But not all preterm infants with RDS can be beneficial. Otherwise, the international neonatal acute RDS (NARDS) collaborative group provides the first consensus definition for NARDS in 2017. And whether or not PS being beneficial in preterm infants with NARDS remains unknown.

NCT ID: NCT04964531 Not yet recruiting - Clinical trials for Patent Ductus Arteriosus

Effect of PDA Closure on the Left Ventricular Remodeling

Start date: July 2021
Phase:
Study type: Observational

failure of closure of the ductus arteriosus after birth results in a congenital anomaly known as patent ductus arteriosus. The large ductus can induce left side heart remodeling changes which could interfere with the normal cardiac function.

NCT ID: NCT04672629 Not yet recruiting - Clinical trials for Patent Ductus Arteriosus

Clinical Profile of Neonates Having Patent Ductus Arteriosus

Start date: April 1, 2021
Phase:
Study type: Observational

The study aims to evaluate the clinical presentation and course of PDA diagnosed at neonatal period in the neonatology unit of Assiut University Hospital for Children.